Ventyx Biosciences (VTYX)
(Delayed Data from NSDQ)
$2.53 USD
-0.05 (-1.94%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $2.52 -0.01 (-0.40%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VTYX 2.53 -0.05(-1.94%)
Will VTYX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VTYX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VTYX
Ventyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It Mean for the Stock?
VTYX Stock Rises on Strategic Equity Investment Deal With SNY
VTYX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for VTYX
Commit To Buy Ventyx Biosciences At $2.50, Earn 56.9% Annualized Using Options
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Ventyx Biosciences (VTYX)
Oppenheimer Reaffirms Their Buy Rating on Ventyx Biosciences (VTYX)
Hold Rating for Ventyx Biosciences Amid Promising Early Data and Strategic Uncertainties
Positive Outlook on Ventyx Biosciences Due to Promising Developments in Neuro-Inflammatory Treatments